Lipicare Pharmaceuticals

Company Overview

Snapshot

Founded in June 2016 by Rafael Ezra, Lipicare Pharmaceuticals operates with 1–10 employees. The company has secured funding across one round, with BIOLIGHT Life Sciences identified as a lead investor. A key development for Lipicare Pharmaceuticals was the agreement for manufacturing and distribution in Europe for its product aimed at alleviating symptoms from screen exposure, signaling a strategic move into the European market.

Business overview

Lipicare Pharmaceuticals specializes in developing ophthalmic products utilizing nano-emulsions of phospholipids to efficiently and comfortably deliver fatty medications to the ocular surface. The company's core product, Ocular D, is designed to treat dry eye syndrome with integrated vitamin D, and has demonstrated potential in blocking blue light radiation. Lipicare Pharmaceuticals primarily serves the Health Tech & Life Sciences sector, focusing on medical products, drug delivery, and pharmaceuticals, with a strategic emphasis on the European market.

Strategic signal

In July 2021, Lipicare Pharmaceuticals secured a manufacturing and distribution agreement in Europe for its product addressing symptoms related to screen exposure. This development is significant as it indicates the company's progress towards commercialization and market expansion, particularly in the European Union, following the anticipated CE approval for its Ocular-D product. For investors, this signals a clear pathway to market entry and revenue generation, validating the company's product development and regulatory strategy.

Company Intelligence Q&A

What is Lipicare Pharmaceuticals' primary focus?

Lipicare Pharmaceuticals focuses on developing products based on nano-emulsions of phospholipids for effective and comfortable delivery of fatty medications to the ocular surface.

What is Ocular D?

Ocular D is Lipicare Pharmaceuticals' first commercial product, designed to treat dryness in the eye with integrated vitamin D. Laboratory testing has also shown it helps block blue light radiation.

When was Lipicare Pharmaceuticals founded?

Lipicare Pharmaceuticals was founded in June 2016.

Which investor participated in Lipicare Pharmaceuticals' funding round?

In December 2019, Lipicare Pharmaceuticals received funding from BIOLIGHT Life Sciences.

What is the significance of the European manufacturing and distribution agreement?

In July 2021, Lipicare Pharmaceuticals secured an agreement for manufacturing and distribution in Europe for its product addressing symptoms from screen exposure, indicating a strategic move towards commercialization and market entry in the region.